Management of patients with chronic lymphocytic leukemia during the SARS‑CoV‑2 pandemic (Review)

Mihaila,Romeo Gabriel

doi:10.3892/ol.2021.12897

Management of patients with chronic lymphocytic leukemia during the SARS‑CoV‑2 pandemic (Review)

Authors:
- Romeo Gabriel Mihaila
View Affiliations

Affiliations: Department of Hematology, Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania
Published online on: July 3, 2021 https://doi.org/10.3892/ol.2021.12897
Article Number: 636
Copyright: © Mihaila . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oncohematological patients are prone to develop infections due to immunosuppression caused by the disease and chemo‑immunotherapy. The aim of this review was to outline the details of the management of patients with chronic lymphocytic leukemia (CLL) during the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) pandemic. Patients with CLL often exhibit inadequate humoral and cellular immune responses to various infections and vaccinations. Patients under the ‘watch and wait’ strategy have a lower risk of infections, including with SARS‑CoV‑2, compared with those undergoing therapeutic interventions, but they still have a higher risk than age‑matched controls. Patients with CLL have a high risk of developing severe forms of coronavirus disease‑2019 (COVID‑19), particularly if they are undergoing chemo‑immunotherapy. The total anti‑SARS‑CoV‑2 antibody titer demonstrates a slower increase in patients with CLL infected with the virus, and the antibody levels tend to decrease after reaching a maximum level sooner than in healthy individuals. This leads to a late negativation of the PCR tests and a longer duration of hospitalization. In total, ~1/3 of patients with CLL do not develop a persistent titer of antiviral antibodies, and this is associated with the presence of hypogammaglobulinemia. It appears that patients with CLL have the worst outcomes amongst patients with malignant hemopathies and SARS‑CoV‑2 infection. Bruton tyrosine kinase inhibitors reduce the hyperinflammatory status of patients with CLL with COVID‑19, which is accompanied by decreased levels of serum inflammatory markers, ferritin and D‑dimer, and serum levels of pro‑inflammatory cytokines, but they increase the risk of infections and impaired humoral immunity. An abrupt discontinuation of these may promote the rapid decompensation of CLL, which may even mimic the clinical manifestations of COVID‑I9, including a significant increase in cytokine release. In conclusion, therapeutic decisions must be personalized to each patient with CLL and each at risk patient must be quarantined during the SARS‑CoV‑2 pandemic to reduce their risk of contraction.

View Figures

View References

1	Cuneo A, Scarfò L, Reda G, Varettoni M, Quaglia FM, Marchetti M, De Paoli L, Re F, Pietrasanta D, Rigolin GM, et al: Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report. Blood. 136:763–766. 2020. View Article : Google Scholar : PubMed/NCBI
2	Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen P, et al: Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 32:23–33. 2021. View Article : Google Scholar : PubMed/NCBI
3	Riches JC and Gribben JG: Understanding the immunodeficiency in chronic lymphocytic leukemia: Potential clinical implications. Hematol Oncol Clin North Am. 27:207–235. 2013. View Article : Google Scholar : PubMed/NCBI
4	Fürstenau M, Langerbeins P, De Silva N, Fink AM, Robrecht S, von Tresckow J, Simon F, Hohloch K, Droogendijk J, van der Klift M, et al: COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia. 34:2225–2229. 2020. View Article : Google Scholar
5	Paneesha S, Pratt G, Parry H and Moss P: Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia. Leuk Res. 93:1063662020. View Article : Google Scholar : PubMed/NCBI
6	Williams AM, Baran AM, Meacham PJ, Feldman MM, Valencia HE, Newsom-Stewart C, Gupta N, Janelsins MC, Barr PM and Zent CS: Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. Leuk Lymphoma. 59:625–632. 2018. View Article : Google Scholar : PubMed/NCBI
7	Sehn LH, Kuruvilla P, Christofides A and Stakiw J: Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic. Curr Oncol. 27:e332–e335. 2020. View Article : Google Scholar : PubMed/NCBI
8	Charra B, Ellouadghiri A, Magramane A, Kebbou T, Damaan K, Maghfour A, Seddiki K and Ezzouine H: COVID-19 and fortuitous discovery of chronic lymphocytic leukemia: Biological findings and therapeutic challenges. Pan Afr Med J. 36:2862020. View Article : Google Scholar : PubMed/NCBI
9	Koffman B, Mato A, Byrd JC, Danilov A, Hedrick B, Ujjani C, Roeker L, Stephens DM, Davids MS, Pagel JM and Shadman M: Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol. 95:E199–E203. 2020. View Article : Google Scholar : PubMed/NCBI
10	Strati P and Shanafelt TD: Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: Diagnosis, natural history, and risk stratification. Blood. 126:454–462. 2015. View Article : Google Scholar : PubMed/NCBI
11	Thibaud S, Tremblay D, Bhalla S, Zimmerman B, Sigel K and Gabrilove J: Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19. Br J Haematol. 190:e73–e76. 2020. View Article : Google Scholar : PubMed/NCBI
12	Sanchez-Pina JM, Rodríguez Rodriguez M, Castro Quismondo N, Gil Manso R, Colmenares R, Gil Alos D, Paciello ML, Zafra D, Garcia-Sanchez C, Villegas C, et al: Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. Eur J Haematol. 105:597–607. 2020. View Article : Google Scholar : PubMed/NCBI
13	Molina-Cerrillo J, Marquet-Palomanes J, Alonso-Gordoa T, López-Jiménez J and Grande E: May ibrutinib have activity in respiratory complications by SARS-CoV-2? Clinical experience in a patient with chronic lymphocytic leukemia. Healthcare (Basel). 9:782021. View Article : Google Scholar : PubMed/NCBI
14	Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernandez-Rivas JÁ, Mirás F, Baile M, et al: COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: A joint study by ERIC, the European research initiative on CLL, and CLL Campus. Leukemia. 34:2354–2363. 2020. View Article : Google Scholar
15	Agha M, Blake M, Chilleo C, Wells A and Haidar G: Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. medRxiv. doi: 10.1101/2021.04.06.21254949 (Preprint). PubMed/NCBI
16	Poh AR, O'Donoghue RJ and Ernst M: Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells. Oncotarget. 6:15752–15771. 2015. View Article : Google Scholar : PubMed/NCBI
17	Stack M, Sacco K, Castagnoli R, Livinski AA, Notarangelo LD and Lionakis MS: BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review. Res Sq. doi: 10.21203/rs.3.rs-319342/v1 (Preprint). PubMed/NCBI
18	Roosta Y, Behzadi F, Askari E, Raeisi M, Danandeh Mehr A and Nouri-Vaskeh M: Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges. Leuk Res Rep. 15:1002392021.PubMed/NCBI
19	Rossi D, Shadman M, Condoluci A, Brown JR, Byrd JC, Gaidano G, Hallek M, Hillmen P, Mato A, Montserrat E and Ghia P: How we manage patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic. Hemasphere. 4:e4322020. View Article : Google Scholar : PubMed/NCBI
20	Jacque N and Leblond V: La leucémie lymphoïde chronique: Mise au point. Presse Med. 48:807–815. 2019. View Article : Google Scholar : PubMed/NCBI
21	Ali E, Badawi M, Abdelmahmuod E, Kohla S and Yassin MA: Chronic lymphocytic leukemia concomitant with COVID 19: A case report. Am J Case Rep. 21:e9260622020. View Article : Google Scholar : PubMed/NCBI
22	Ting FI, Sacdalan DB, Cortez JL, Pacana MAD and Jimeno C: COVID-19 in cancer patients can be challenging to screen in a resource limited setting. Cancer Treat Res Commun. 25:1002142020. View Article : Google Scholar : PubMed/NCBI
23	Ye X, Xiao X, Li B, Zhu W, Li Y, Wu J, Huang X, Jin J, Chen D, Jin J and Huang J: Low humoral immune response and ineffective clearance of SARS-Cov-2 in a COVID-19 patient with CLL during a 69-day follow-up. Front Oncol. 10:12722020. View Article : Google Scholar : PubMed/NCBI
24	Alves Barbosa O, Guimarães Andrade T, de Almeida Sousa MD and Correia JW: COVID-19 in a patient with chronic lymphocytic leukaemia with pseudohypoxemia. Eur J Case Rep Intern Med. 7:0017632020.PubMed/NCBI
25	Roeker LE, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA, Zelenetz AD and Mato AR: Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 34:3047–3049. 2020. View Article : Google Scholar : PubMed/NCBI
26	Sinisalo M, Aittoniemi J, Käyhty H and Vilpo J: Vaccination against infections in chronic lymphocytic leukemia. Leuk Lymphoma. 44:649–652. 2003. View Article : Google Scholar : PubMed/NCBI
27	Favresse J, Eucher C, Elsen M, Graux C, Goebels P, Laffineur K, Nicolas JB, Dogné JM and Douxfils J: Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia. Br J Haematol. 190:e187–e189. 2020. View Article : Google Scholar : PubMed/NCBI
28	Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, Barbian K, Judson SD, Fischer ER, Martens C, et al: Case study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 183:1901–1912.e9. 2020. View Article : Google Scholar : PubMed/NCBI
29	Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, et al: Outcomes of COVID-19 in patients with CLL: A multicenter international experience. Blood. 136:1134–1143. 2020. View Article : Google Scholar : PubMed/NCBI
30	Baumann T, Delgado J and Montserrat E: CLL and COVID-19 at the hospital clinic of Barcelona: An interim report. Leukemia. 34:1954–1956. 2020. View Article : Google Scholar : PubMed/NCBI
31	Muntañola A, Villacampa G, Hernández-Rivas JÁ, Alonso R, Mirás F, Osorio S, Baile M, Baltasar P, López Jiménez J, Hernandez-Rodriguez I, et al: Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country. Exp Hematol Oncol. 9:372020. View Article : Google Scholar
32	Reda G, Noto A, Cassin R, Zamprogna G, Borella C, Scarfò L, Farina L, Molteni A, Ghia P, Tedeschi A, et al: Reply to ‘CLL and COVID-19 at the hospital clinic of Barcelona: An interim report’ analysis of six hematological centers in Lombardy: On behalf of CLL commission of Lombardy hematology network (REL). Leukemia. 34:2531–2532. 2020. View Article : Google Scholar : PubMed/NCBI
33	Zhang C, Wu Z, Li JW, Zhao H and Wang GQ: The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 55:1059542020. View Article : Google Scholar : PubMed/NCBI
34	Miossec P and Kolls JK: Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 11:763–776. 2012. View Article : Google Scholar : PubMed/NCBI
35	Montserrat E: When CLL meets COVID-19. Blood. 136:1115–1116. 2020. View Article : Google Scholar : PubMed/NCBI
36	Song SH, Chen TL, Deng LP, Zhang YX, Mo PZ, Gao SC, Hu WJ, Xiong Y and Ma ZY: Clinical characteristics of four cancer patients with SARS-CoV-2 infection in Wuhan, China. Infect Dis Poverty. 9:822020. View Article : Google Scholar : PubMed/NCBI
37	Niu A, McDougal A, Ning B, Safa F, Luk A, Mushatt DM, Nachabe A, Zwezdaryk KJ, Robinson J, Peterson T, et al: COVID-19 in allogeneic stem cell transplant: High false-negative probability and role of CRISPR and convalescent plasma. Bone Marrow Transplant. 55:2354–2356. 2020. View Article : Google Scholar : PubMed/NCBI
38	Xu B, Fan CY, Wang AL, Zou YL, Yu YH, He C, Xia WG, Zhang JX and Miao Q: Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China. J Infect. 81:e51–e60. 2020. View Article : Google Scholar : PubMed/NCBI
39	von Lilienfeld-Toal M, Vehreschild JJ, Cornely O, Pagano L, Compagno F; EHA Infectious Disease Scientific Working Group, ; Hirsch HH: Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases. Leukemia. 34:1487–1494. 2020. View Article : Google Scholar : PubMed/NCBI
40	Helleberg M, Niemann CU, Moestrup KS, Kirk O, Lebech AM, Lane C and Lundgren J: Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 222:1103–1107. 2020. View Article : Google Scholar : PubMed/NCBI
41	Langerbeins P, Fürstenau M, Gruell H, Klein F, Persigehl T, Rybniker J, Seeger-Nukpezah T, Kochanek M, Hallek M, Eichhorst B, et al: COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia. Eur J Haematol. 105:508–511. 2020. View Article : Google Scholar : PubMed/NCBI
42	Lin L, Lu L, Cao W and Li T: Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 9:727–732. 2020. View Article : Google Scholar : PubMed/NCBI
43	Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB and Cheng G: Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 24:44–46. 2005. View Article : Google Scholar : PubMed/NCBI
44	Rada M, Qusairy Z, Massip-Salcedo M and Macip S: Relevance of the bruton tyrosine kinase (BTK) as a target for COVID-19 therapy. Mol Cancer Res. 19:549–554. 2020. View Article : Google Scholar : PubMed/NCBI
45	Chong EA, Roeker LE, Shadman M, Davids MS, Schuster SJ and Mato AR: BTK Inhibitors in cancer patients with COVID-19: ‘The winner will be the one who controls that chaos’ (Napoleon Bonaparte). Clin Cancer Res. 26:3514–3516. 2020. View Article : Google Scholar : PubMed/NCBI
46	Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, Meid K and Yang G: The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 135:1912–1915. 2020. View Article : Google Scholar : PubMed/NCBI
47	Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P and Treon SP: Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. Haematologica. 103:e307–e310. 2018. View Article : Google Scholar : PubMed/NCBI
48	Sun C, Tian X, Lee YS, Gunti S, Lipsky A, Herman SE, Salem D, Stetler-Stevenson M, Yuan C, Kardava L, et al: Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 126:2213–2219. 2015. View Article : Google Scholar : PubMed/NCBI
49	de Weerdt I, Hofland T, de Boer R, Dobber JA, Dubois J, van Nieuwenhuize D, Mobasher M, de Boer F, Hoogendoorn M, Velders GA, et al: Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Adv. 3:2642–2652. 2019. View Article : Google Scholar : PubMed/NCBI
50	Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG and Gribben JG: T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 121:1612–1621. 2013. View Article : Google Scholar : PubMed/NCBI
51	Di Ciaccio P, McCaughan G, Trotman J, Ho PJ, Cheah CY, Gangatharan S, Wight J, Ku MH, Quach H, Gasiorowski R, et al: Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Intern Med J. 50:667–679. 2020. View Article : Google Scholar : PubMed/NCBI
52	Cordoba R: Bringing hospital care closer to patients amidst COVID-19. Lancet Haematol. 7:e6372020. View Article : Google Scholar : PubMed/NCBI
53	American Society of Hematology (ASH), . COVID-19 and CLL: Frequently asked questions. ASH; Washington, DC: 2020, http://www.hematology.org/covid-19/covid-19-and-cllLast updated February 2, 2021.